Source Articles
Cetuximab
Showing 7 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | Anti-EGFR mAb | Cetuximab | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — | — | — |
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | Anti-EGFR mAb | Cetuximab | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — | — | — |
| Huang et al. | 2022 | Retrospective | Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer | 10.1016/j.bj.2021.10.013 | — | 74 | 58 | Head and neck cancer | metastatic | Anti-EGFR mAb | Cetuximab | — | 74 | extra-cranial | cervical lymph nodes | primary head and neck tumor | 40 | 40.0 | 50.0 | 5 | 5 | 5 | 8 | 8 | 10 | RT-related | 13 | 15 | — | acute G3: 13 AEs, late G>=3: 15 AEs | acute G3: 13 pts, late G>=3: 15 pts | acute G3: mucositis, radiation dermatitis, late G>=3: dysphagia and/or laryngeal edema, osteonecrosis or soft tissue necrosis, carotid blowout. | acute G3: mucositis, radiation dermatitis, late G>=3: dysphagia and/or laryngeal edema, osteonecrosis or soft tissue necrosis, carotid blowout. |
| Quan et al. | 2016 | Retrospective | Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma | 10.1016/j.semradonc.2015.11.007 | — | 18 | 64 | Head and neck cancer | primary | Anti-EGFR mAb | Cetuximab | — | 18 | extra-cranial | other | recurrent head and neck tumor | 40 | 40.0 | 44.0 | 5 | 5 | 5 | 8 | 8 | 8, 8 | Treatment-rel. | — | — | 1 | any G3: 2 AEs | any G3: 1 pt | any G3: mucositis, rash (erbitux) | any G3: mucositis |
| Vargo et al. | 2015 | Prospective | A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck | 10.1016/j.ijrobp.2014.11.023 | NCT 01104922 | 48 | 63 | Head and neck cancer | primary | Anti-EGFR mAb | Cetuximab | — | 48 | extra-cranial | other | recurrent head and neck tumor | Missing | 40.0 | 44.0 | 5 | 5 | 5 | Missing | 8 | 8.8 | Treatment-rel. | 3 | 3 | — | acute G3: 4 AEs, late G3: 3 AEs | acute G3: 3 pts, late G3: 3 pts | acute G3: mucositis/skin, dysphagia, skin, late G3: dypshagia, aerodigestive fistula | acute G3: mucositis/skin, dysphagia, skin, late G3: dypshagia, aerodigestive fistula |
| Vargo et al. | 2014 | Retrospective | Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume | 10.1002/hed.23462 | — | 132 | 66 | Head and neck cancer | any | Anti-EGFR mAb | Cetuximab | — | Missing | extra-cranial | other, cervical lymph nodes | head and neck | 44 | 35.0 | 50.0 | 5 | 5 | 5 | Missing | Missing | Missing | Treatment-rel. | 16 | 6 | — | acute G3-4: 19 AEs, late G3: 6 AEs | acute G3-4: 16 pts, late G3: 6 pts | acute G3-4: Mucositis, dysphagia, skin reactions, xerostomia, dysgeusia, pain, fatigue, late G3: Dysphagia, skin reactions, pain, osteonecrosis | — |
| Lartigau et al. | 2013 | Prospective | Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer | 10.1016/j.radonc.2013.08.012 | Missing | 56 | 60 | Head and neck cancer | primary | Anti-EGFR mAb | Cetuximab | — | 56 | extra-cranial | other | head and neck | 36 | 36.0 | 36.0 | 6 | 6 | 6 | 6 | 6 | 6 | Treatment-rel. | — | — | 19 | any G3: 18 AEs, any G5: 1 AE | any G3: 18 pts, any G5: 1 pt | any G3: mucositis, cutaneous toxicity, rash, fibrosis, dysphagia, xerostomia, fistula, dysgeusia, any G5: hemorrhage and denutrition | unknown |